文献速递肿瘤 PET/CT

18F-FDG PET/CT代谢参数联合其他临床特征与非小细胞肺癌ALK或ROS1融合的相关性

Correlation between combining 18F-FDG PET/CT metabolic parameters and other clinical features and ALK or ROS1 fusion in patients with non-small-cell lung cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-01-03

研究纳入806例表皮生长因子受体(EGFR)突变野生型、治疗前接受18F-FDG PET/CT的非小细胞肺癌(NSCLC)患者,分析ALK或ROS1融合与临床特征及PET/CT参数的关系。多因素分析显示高pSUVmax、低pTLG、年轻、不吸烟及高癌胚抗原(CEA)与ALK融合相关,高pSUVmax、年轻及不吸烟与ROS1融合相关;联合参数模型AUC分别达0.873和0.813,作者认为可能有助于优化靶向治疗前基因检测的患者选择。

要点

  • 806例EGFR野生型NSCLC中ALK融合82例(11.7%),ROS1融合26例(5.6%)。
  • ALK融合相关因素:pSUVmax≥10.6、pTLG<101.8、年轻、不吸烟、高CEA。
  • ROS1融合相关因素:pSUVmax≥8.8、年轻、不吸烟;联合模型AUC 0.813。

核心结论

  • 联合18F-FDG PET/CT代谢参数与其他临床参数与NSCLC患者ALK和ROS1突变相关,可能有助于优化靶向治疗前基因检测的患者选择。

研究设计与样本

  • 在本院筛选806例表皮生长因子受体(EGFR)突变野生型、治疗前接受18F-FDG PET/CT的非小细胞肺癌(NSCLC)患者进行ALK或ROS1融合检测。
  • 分析ALK或ROS1融合与临床特征及PET/CT参数的关联,并采用多因素logistic回归分析探索独立决定因素。

主要发现

  • 806例中检出ALK融合82例(11.7%),ROS1融合26例(5.6%)。
  • 多因素分析显示高pSUVmax≥10.6、低pTLG<101.8、年轻、不吸烟状态及高癌胚抗原(CEA)水平与NSCLC中ALK融合相关。
  • 仅高pSUVmax单独预测ALK融合的ROC曲线AUC为0.603,五因素联合的AUC为0.873。
  • 多因素分析显示高pSUVmax≥8.8、年轻及不吸烟状态与NSCLC中ROS1融合相关。
  • 仅高pSUVmax单独预测ROS1融合的ROC曲线AUC为0.662,三因素联合的AUC为0.813。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Our study intended to explore the association between combining 18F-FDG PET/CT metabolic parameters and other clinical features and anaplastic lymphoma kinase (ALK) or c-ros oncogene 1 (ROS1) fusion in non-small-cell lung cancer (NSCLC). METHODS: Eight hundred and six patients with wild-type epidermal growth factor receptor (EGFR) mutation were screened for ALK or ROS1 fusion and subjected to 18F-FDG PET/CT prior to treatment at our hospital. The associations between ALK or ROS1 fusion and clinical characteristics and the PET/CT parameters were analyzed. Multivariate logistic regression analysis was performed to explore independent deterministic factors associated with ALK and ROS1 fusion. RESULTS: Eighty-two patients (11.7%) with ALK fusion were found. Multivariate analysis demonstrated that high pSUVmax ≥ 10.6, low primary tumor lesion glycolysis (pTLG) < 101.8, young age, nonsmoker status, and high carcinoembryonic antigen (CEA) level correlated with ALK fusion in NSCLC. The receiver operating characteristic (ROC) curve yielded the area under curve (AUC) values of 0.603 and 0.873 for high pSUVmax alone and the combination of the five factors, respectively. Twenty-six patients (5.6%) with ROS1 fusion were found. Multivariate analysis revealed that high pSUVmax ≥ 8.8, young age, and nonsmoker status correlated with ROS1 fusion in NSCLC. The ROC curve yielded AUC values of 0.662 and 0.813 for high pSUVmax alone and the combination of the three factors, respectively. CONCLUSION: The study indicated that combining 18F-FDG PET/CT metabolic parameters and other clinical parameters were correlated with ALK and ROS1 mutation in NSCLC patients and may help to refine the process of optimal patient selection to gene test for targeted therapy.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Ruan M, Liu L, Wang L, et al. Correlation between combining 18F-FDG PET/CT metabolic parameters and other clinical features and ALK or ROS1 fusion in patients with non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2020. PMID: 31897590. doi:10.1007/s00259-019-04652-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。